1. Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma—backbone or add-on in immune-oncology?
   Christin Riess et al, 2021, Cancer and Metastasis Reviews CrossRef
2. Potent Activity of a Novel Dimeric Heat Shock Protein 90 Inhibitor against Head and Neck Squamous Cell Carcinoma In vitro and In vivo
   Xiaoying Yin et al, 2005, Clinical Cancer Research CrossRef
3. Synergistic Inhibition of ErbB Signaling by Combined Treatment with Seliciclib and ErbB-Targeting Agents
   Ian N. Fleming et al, 2008, Clinical Cancer Research CrossRef
4. Accumulation of p53 and Reductions in XIAP Abundance Promote the Apoptosis of Prostate Cancer Cells
   Subhra Mohapatra et al, 2005, Cancer Research CrossRef
5. Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells
   Mohamed Salah I Abaza et al, 2008, World Journal of Gastroenterology CrossRef
6. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma
   Noopur Raje et al, 2005, Blood CrossRef
7. Protection of renal cells from cisplatin toxicity by cell cycle inhibitors
   Peter M. Price et al, 2004, American Journal of Physiology-Renal Physiology CrossRef